Indian firms selling SAAS products have got a bonanza as companies meet, manage and sell remotely. The top five firms - Zoho, Freshworks HighRadius, Druva, and Icertis - account for 33 per cent of the market share. Chennai, India's SAAS centre, alone generates $1 billion in annual revenue. Yuvraj Malik explains how these companies are planning their next phase of growth.
The OTC major plans to pump in millions of dollars into Vedants' manufacturing facility coming up by 2011 at Ambernath near Mumbai. Perrigo will then move production of active pharmaceutical ingredients (APIs or the key therapeutic substance in a drug) from its sites in Germany and Israel to India.
This mindless medley of products does not create choice.
For instance, Dr Reddy's Laboratories has six active pharmaceutical units in Andhra Pradesh. The waste streams from the API units mostly contain potassium sulphate, caustic lye, potassium chloride, potassium sulphate and sodium sulphate salts.
Guardian enables users to switch on a 'track me' feature in the app that lets friends and family track them in real-time using Microsoft Windows Azure cloud services and Bing Map APIs, the company said.
Experts say while the increasing demand for a ban on Chinese goods might make for good optics, the reality is that India is still heavily dependent on that country in a wide range of industries like electronics, mobile devices, auto, pharma, telecom equipment, and fertilisers.
Gold, forex assets, IT sector, pharma. Devangshu Datta explains why each of these is a good hedge against market shocks at this time.
A study by a Swedish University has accused India's Active Pharmaceutical Ingredient (API) manufacturers of causing alarming levels of environmental pollution and threatening the region's flora and fauna.
To address the supply crunch, CII has suggested leveraging the existing excess capacity in the Indian industry; rolling back import duty hike to look for alternative sources of imports; expanding credit to manufacturing units with quick loan sanctions, and one-time emergency waiver of non-performing asset regulations for three months.
Unitech is pinning its hopes on the sub-Rs 5 lakh category of flats to counter the slowdown in the property sector. So are a host of others. Apart from Unitech, others such as Omaxe, Raheja, Tata Housing and Ansal API are planning new projects in the suburbs of satellite towns or smaller cities to target the bottom segment, to generate more cash.
Besides looking to grow through the inorganic route, the company has embarked on an expansion strategy by planning to set up four manufacturing plants at Bavla in Gujarat.
A day after getting a show-cause notice from the Indian regulator, senior executives from Ranbaxy Laboratories approached the drug controller's office on Tuesday afternoon, it was learnt.
Ranbaxy Laboratories, India's biggest drugmaker, may lose as much as $140 million of revenue in 2009 after the US drug regulator blocked sale of more than 30 generic medicines and 7 APIs made in two factories of the company, according to analysts.
Prajnesh, India's top-ranked singles player at 122, downed the local wild card Jason Kubler 7-5, 6-3 in the first round
Ankleshwar plant is the third such facility to face action
Hetero Drugs, the Hyderabad-based active pharmaceutical ingredients and finished dosages manufacturer, has set up an equal stakes joint venture with Russian pharmaceutical major Makiz Pharma.
A key lesson for the pharmaceutical sector in this case is to not downplay the significant impact that regulatory non-compliance can have on operations.
It is domestic policy distortions and inaction to correct them that lie behind the large CADs.
SMS Pharmaceuticals, a bulk drug manufacturer, is raising funds to augment capacity.
Global pharmaceutical major Teva is planning collaborations with Indian partners for clinical research and biotechnology.
Dr Reddy's on Monday said it would acquire Switzerland-based Roche's bulk drug business in Mexico for $59 million.
Aurobindo Pharma on Thursday said it had received US FDA approval for anti-retroviral Lamivudine, thus enabling it to participate in the president's emergency plan for AIDS relief), a US government initiative.
The court said the Criminal Investigation Department had failed to produce substantial evidence against the accused.
Real estate firm Ansal Properties and Infrastructure Ltd plans to invest Rs 30,000 crore (Rs 300 billion) to develop 16 townships in north India during next 3-4 years.
The stock faced similar trends on the National Stock Exchange as well, where it opened at Rs 362, then plunged 2.70 per cent to an early low of Rs 354.10.
An analysis of 3,840 Instagram photos from New York, London, Berlin, Moscow, Bangkok and Sao Paulo - 640 for each city -- found that just four per cent of then were actually selfies.
Lupin proposes to set up a sector-specific special economic zone in Maharashtra to produce API and formulations with an initial investment of Rs 200 crore (Rs 2 billion).
Tamal Bandyopadhyay details HDFC Bank's digital journey.
Slapped with Rs 242-crore fine by US authorities for rule violations at Toansa unit, say sources; 2nd such hefty rap in the recent past from US regulators for bending rules.
It takes eight to nine months for developing a robust software from the time the rules are decided, warns Bharat Goenka, managing director of Tally Solutions, one of the entities entrusted as a 'Suvidha Provider' with developing ready software for customers to get them ready for the coming Goods and Services Tax.
The solutions developed by the company cover a broad spectrum, including helping recruiter's gauge the behavioural profiles of candidates during virtual job interviews and assisting in real-time translation in vernacular languages, among others.
According to reports, the deal is estimated to be close to $300 mn.
'What amazes me the most is that today users communicate with voice-activated speakers like as if they were talking to another human being, using words like "please," and "thank you," and even "sorry"!', says advertising guru Sandeep Goyal.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances